Biocon Launches Bosaya & Aukelso in U.S. to Challenge $5B Bone Health Market

Biocon Enters U.S. Market with Key Biosimilars

Biocon Limited, a global biopharmaceutical company based in India, announced on April 7, 2026, the commercial launch of two significant biosimilar products, Bosaya™ (denosumab-kyqq) and Aukelso™ (denosumab-kyqq), in the United States. This strategic move positions Biocon to compete in the lucrative U.S. bone health market, targeting conditions like osteoporosis and bone complications from cancer. The products are now available by prescription through specialty pharmacies and healthcare providers across the nation.

Regulatory Approval and Interchangeability

The launch follows the U.S. Food and Drug Administration (FDA) approval granted in September 2025. Critically, both Bosaya™ and Aukelso™ received an interchangeable designation. This status allows pharmacists to substitute the biosimilar for the reference product at the pharmacy level, in accordance with state laws, without needing to consult the prescribing physician. This designation is expected to facilitate faster adoption and increase patient access to more affordable treatment options.

Bosaya™ is a biosimilar to Amgen's Prolia®, while Aukelso™ is a biosimilar to Amgen's Xgeva®. These reference products are widely used and play a crucial role in managing serious bone-related health issues.

A Strategic Expansion for Biocon

Shreehas Tambe, CEO and Managing Director of Biocon Limited, emphasized the importance of this launch. He stated, “The U.S. introduction of Bosaya™ and Aukelso™ marks a strategic expansion of our biosimilars portfolio, building on our established leadership in oncology and immunology.”

Tambe further noted that these therapies broaden access to high-quality, affordable treatment options for patients. He described the milestone as an indicator of Biocon's strength in portfolio development and its focus on creating a scalable global access platform for life-changing medicines.

Tapping into a Multi-Billion Dollar Market

The market for denosumab products in the United States is substantial. In 2024, sales for these treatments generated approximately $1 billion, highlighting a significant need for effective therapies. The patient population is large, with an estimated 10 million adults in the U.S. living with osteoporosis. Additionally, over 330,000 patients annually are diagnosed with bone metastasis, a common and serious complication of advanced cancer.

Biocon's entry with interchangeable biosimilars is poised to introduce competition, which could help lower healthcare costs for both patients and the overall system.

Product Details and Availability

Biocon has made both biosimilars available in their most common presentations to ensure a smooth transition for healthcare providers and patients.

These formulations are identical to those of their reference products, ensuring consistency in administration and dosage for subcutaneous use.

The Path to Commercialization

The commercial launch was preceded by a key legal development. In October 2025, Biocon's subsidiary, Biocon Biologics, announced a settlement and license agreement with Amgen Inc. This agreement resolved pending patent litigation in the U.S. District Court for the District of New Jersey, officially clearing the path for Biocon to bring Bosaya™ and Aukelso™ to the U.S. market. The specific financial terms of the settlement remain confidential.

Impact on Patients and the Healthcare System

The availability of Bosaya™ and Aukelso™ is expected to have a positive impact on the U.S. healthcare landscape. Biosimilars are designed to be as safe and effective as their original biologic counterparts but are typically offered at a lower cost. For chronic conditions like osteoporosis or for long-term cancer care, the savings can be significant for patients and insurers.

The interchangeable status further simplifies the process, making it easier for patients to access these more affordable alternatives. This launch aligns with the broader healthcare goal of increasing competition and reducing prescription drug spending.

About Biocon Limited

Headquartered in Bengaluru, India, Biocon Limited (BSE: 532523, NSE: BIOCON) is an innovation-led biopharmaceutical company focused on providing affordable access to complex therapies for chronic diseases such as diabetes, cancer, and autoimmune disorders. The company has a diversified portfolio of biosimilars and generics, with a global footprint. To date, Biocon has successfully commercialized 12 biosimilar products and over 30 generic formulations worldwide, reinforcing its position as a key player in the global pharmaceutical industry.